EU/3/16/1613

About

On 17 February 2016, orphan designation (EU/3/16/1613) was granted by the European Commission to RV Developpement, France, for tolfenamic acid for the treatment of progressive supranuclear palsy.

Key facts

Active substance
Tolfenamic acid
Disease / condition
Treatment of progressive supranuclear palsy
Date of first decision
17/02/2016
Outcome
Positive
EU designation number
EU/3/16/1613

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

RV Developpement
5 Résidence des Prés
57510 Puttelange-aux-Lacs
France
Tel. +33 6761 76159
E-mail: raphael.vico@adscientific.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating